CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
83 hedge funds and large institutions have $200M invested in CTI BioPharma Corp. (DE) Common Stock in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 15 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
136% more call options, than puts
Call options by funds: $512K | Put options by funds: $217K
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more capital invested
Capital invested by funds: $142M → $200M (+$59M)
24% more funds holding
Funds holding: 67 → 83 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.51M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.07M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.78M |
| 2 |
Goldman Sachs
New York
|
-$1.49M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$806K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$767K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$656K |
CTIC Hedge Fund Activity: Q2 2018 in Review
83 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2018, worth a combined $200M — up 42% from $142M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CTIC positions and 15 closed out — a net gain of 16 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $10.4M. The largest seller was Stonepine Capital Management, cutting an estimated $4.78M.
- 83 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2018, up from 67 in Q1 2018.
- Funds reported $200M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2018, up 42% quarter-over-quarter.
- 31 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2018 and 15 closed out, a net change of +16 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2018 was BlackRock, an estimated $10.4M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2018 was Stonepine Capital Management, an estimated $4.78M sold.
Based on aggregated 13F filings for Q2 2018.